Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria.
Nurs Womens Health
; 24(5): 377-382, 2020 Oct.
Article
em En
| MEDLINE
| ID: mdl-32890463
ABSTRACT
In 2019, the U.S. Food and Drug Administration approved cefiderocol, a new treatment option for individuals with complicated urinary tract infections. Cefiderocol is a cephalosporin antibiotic indicated for use in adults 18 years or older who have minimal treatment options due to resistance for complicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex. The recommended dose of cefiderocol is 2 g intravenously every 8 hours infused over 3 hours. The dose is adjusted for individuals with creatinine clearance of less than 60 ml/min or greater than 120 ml/min. Gastrointestinal symptoms such as diarrhea and constipation are the most common adverse events reported by individuals taking cefiderocol.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções Urinárias
/
Cefalosporinas
/
Farmacorresistência Bacteriana Múltipla
/
Bactérias Gram-Negativas
/
Antibacterianos
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article